Clinical Trial Update: A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for BMS-986251 (oral) in healthy participants and patients with psoriasis and rheumatoid arthritis; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis
• Rheumatoid Arthritis

Drugs mentioned

• BMS-986251

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Rheumatoid Arthritis, Psoriasis | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-10-21